Radiopharma's Scale Test
The case for connecting industrial choice with product-specific proof.
EANM 2026 brought new clinical disclosures alongside announcements about isotope access, equipment and manufacturing. This report asks how those developments connect: what makes an alternative supply route usable for a particular product, what the evidence actually establishes, and which operating milestones would strengthen or weaken the case over the next year.
October 2026 · Research cut-off: 21 October 2026
What this report answers
- What did the congress add to the evidence, and what was announced before it?
- When does more isotope access become a usable manufacturing route?
- What can early clinical findings establish about dose, molecular quantity and target selection?
- Where could manufacturers, suppliers and specialist clinical providers create value?
- What would have to happen by October 2027 for the forecasts to hold?
8 layers
The report follows the industry from precursor enrichment to diagnostics and imaging.
6 forecasts
Explicit evidence tests to revisit through October 2027, not assurances of commercial or clinical outcomes.
What the analysis establishes
Eight connected industry layers
The analysis follows precursor enrichment, isotope production, equipment, manufacturing, developers, clinical services, distribution and imaging. Each layer ends with a practical decision and the next evidence to seek.
The clinical evidence in context
Case studies examine molecular quantity, target selection and alpha therapeutic development. Preliminary cohorts, selected analyses and company-reported findings retain their limits; evidence from different products is not combined into an efficacy claim.
Six forecasts with explicit tests
The scorecard sets out observable disclosure tests through October 2027, alongside the countercase that capacity could remain the decisive constraint. It gives readers a way to revisit the argument as operating and clinical evidence develops.
A practical operating agenda
Five questions and a twelve-month review calendar turn the analysis into a framework for evaluating supplier alternatives, transfer packages, measurement services and development priorities.
How it was built
A review of 33 linked public references, with a research cutoff of 21 October 2026. The report separates EANM-linked disclosures from adjacent industry announcements, reported facts from interpretation, and forecasts from demonstrated outcomes. Sources include company statements, clinical summaries, regulatory guidance and congress material. The central connection between industrial flexibility and clinical specificity is a hypothesis, not an observed causal relationship.
Who it is for
Radiopharma executives, investors, business development teams, isotope suppliers, CDMOs, and leaders in CMC, quality, clinical development, radiopharmacy and imaging.
What you can use
- A decision-led view of eight connected industry layers.
- Clinical case studies with evidence limits beside the findings.
- Six testable forecasts and a countercase.
- Five operating questions and a review calendar through October 2027.
Contents
- The ProGen view
- Industrial flexibility meets clinical specificity
- Eight ecosystem layers
- Molecular quantity, target selection and alpha therapeutic demand
- Ownership and coordination
- Commercial implications and forecast scorecard
- The strongest countercase
- Operating playbook and the next twelve months
- Research scope and 33 linked references
Among the organisations discussed
ITM, Lumara, NUCLIDIUM, NorthStar, Nusano, Primo, AtomVie, Jubilant, Telix, IBA, Comecer
The full 28-page briefing is free. Tell us where to send it and it downloads immediately.
About ProGen
ProGen combines executive search with market intelligence across complex life-science markets. If the report raises a specific hiring, supply or diligence question, we can help define the work.
Evidence around a defined market, competitor, supply or investment question.
VP to C-suite appointments across radiopharma and adjacent advanced modalities.